Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes mellitus~* Have been using a pen device for all diabetes or diabetes-related medications for at least one month prior to screening~* Use a pen device to self-administer greater than 40 units of Lantus, Levemir, and/or NPH in one or more single injections. For split doses, at least one of the injections must deliver more than 40 units.~* Documented hemoglobin A1c (HbA1c) from 5.5% to 9.5%, inclusive~* Self monitor blood glucose at once daily with a memory blood glucose meter, and willing do so at least twice per day for the duration of the study~* On a stable diabetes regimen (insulin and non-insulin meds, diet and exercise) for at least 1 month prior to screening~* Able to read, write and follow instructions in English~Exclusion Criteria:~* Current administration of insulin with a pump.~* Current use a syringe to inject insulin or any diabetes-related medication~* Participation in clinical study BDDC-08-011 or DBC-10-SQUIR05~* History of intravenous drug abuse.~* Current status or history of a medical condition that would contraindicate treatment with study products or other conditions which, in the opinion of the Investigator, would place the subject at risk or potentially confound interpretation of the study results (i.e., recent history of ketoacidosis, hypoglycemic unawareness, etc).~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nano: 4mm x 32G Pen Needle (Type: EXPERIMENTAL): Subjects will use the 4mm x 32G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
- Short: 8mm x 31G Pen Needle (Type: EXPERIMENTAL): Subjects will use the 8 mm x 31G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).